YKYuya Kunisaki

Yuya Kunisaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuya Kunisaki has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An Orally Available Derivative of a Specific CK2 Inhibitor for Regulating Circadian Rhythms and Acute Myeloid Leukemia

    by Tsuyoshi Oshima, Daiki Setoyama, Akiko Sugiyama, Kazuma Amaike, Ikumi Yamanaka, Kentaro Hosokawa, Kazuto Nunomura, Kiyoshi Kawamura, Ashutosh Srivastava, Mui Iida, et al.

    The protein kinase CK2 controls cell cycle, apoptosis, and circadian rhythms. The CK2 inhibitor CX-4945 is in clinical trials for cancer treatment, but it has many off-target proteins. Therefore, the development of a bioavailable and specific CK2 inhibitor has been awaited. We previously discovered a specific CK2 inhibitor, GO289, from cell-based phenotypic screening of circadian clock modulators. However, the low water solubility and metabolic stability of GO289 have limited in vivo applications. Here, we developed GO289 derivatives with higher water solubility and metabolic stability. A derivative, GO847, changed the period length of cellular circadian rhythms similar to GO289 and inhibited the growth of acute myeloid leukemia (AML) cells. A proteomic profiling suggested the effects of GO847 and GO289 on pathways related to mitochondrial function, in addition to well-known CK2 targets: cell cycle, apoptosis, RNA metabolism, and protein synthesis. Consistent with this observation, both compounds impaired the metabolic flexibility of mitochondria in AML cells. After oral administration to mice, GO847 was detected in the plasma, liver, spleen, and bone marrow but not in the brain. Together, the findings show that GO847 is a promising candidate for targeting AML, a malignant blood cancer that requires effective treatment.

  • Open Access

    Multi-Omics Mapping of Human Kidney Reveals Complement-Mediated Cellular Dynamics During Progression of Focal Segmental Glomerulosclerosis

    by Yuya Kunisaki, Sahomi Hayashi, Miyoshi Takeuchi, Toshiaki Nakano, Daiki Setoyama, Sasha Singh, Abhijeet Sonawane, Takaki Iwamoto, Hiroshi Kishimoto, Akihiro Tsuchimoto, et al.

    Focal segmental glomerulosclerosis (FSGS) is a major cause of glucocorticoid-resistant nephrosis, yet its pathogenesis remains unclear. To define the molecular and cellular landscape of FSGS, we employed multi-omics approaches on independent human kidney biopsy cohorts. Proteomics revealed enhanced immune and complement activation. Spatial transcriptomics using a target gene panel constructed from the proteomics highlighted alternative pathway activation driven by complement factor D as a prominent feature. Complement activation emerged in glomeruli alongside altered signaling in podocytes and parietal epithelial cells (PECs): Podocytes displayed reduced PECAM1 and elevated macrophage migration inhibitory factor (MIF) signaling, and PECs display complement and collagen signaling as early events, and progressively acquired cellular activation, prompting glomerular fibrosis. These pathogenic signals propagated into adjacent interstitial regions, paralleling immune cell infiltration and fibrosis. These results uncover dynamics of dysregulated intercellular interactions originated from podocyte and PECs underlying the pathogenesis of FSGS, which provides insights into potential stage-specific interventions.

  • Open Access

    Fully Automated Serum LC-MS/MS Platform and Pediatric Reference Intervals for Organic Acids, Amino Acids, and Acylcarnitines in Children (Ages 0–6 Years): Toward Quantitative Diagnosis of Inborn Errors of Metabolism

    by Yasushi Ueyanagi, Daiki Setoyama, Tsuyoshi Nakanishi, Yuichi Mushimoto, Vlad Tocan, Hironori Kobayashi, Miki Matsui, Shinya Matsumoto, Akiyoshi Fujishima, Taeko Hotta, et al.

    Background/Objectives: Conventional diagnosis of inborn errors of metabolism (IEMs) requires multiple specimen types—urine organic acids, plasma amino acids, and serum acylcarnitines—analyzed on distinct analytical platforms. This multi-assay approach is labor-intensive and limits timely clinical decision making. We aimed to develop a fully automated serum-based LC–MS/MS platform for integrated quantitative metabolite profiling and to establish pediatric reference intervals (RIs) to support diagnostic interpretation. Methods: A fully automated LC–MS/MS system integrated with the CLAM-2030 automated pretreatment module was developed to enable simultaneous quantification of 25 organic acids, 8 amino acids, and 21 acylcarnitines. Analytical performance was assessed for linearity, limits of detection and quantification, precision and accuracy. Serum samples from 296 non-IEM children aged 0–6 years were analyzed to establish pediatric RIs using Box–Cox transformation and Gaussian modeling. Clinical utility was evaluated in sera from 89 patients diagnosed with IEM using z-score-based logistic regression models. Results: The method demonstrated excellent performance, with linearity (r2 > 0.99) across calibration ranges, limits of detection and quantification defined by signal-to-noise ratios > 3 and >10, and intra- and inter-assay precision < 15% CV for all 54 analytes. Twenty-one analytes met the acceptance criterion of ±20% accuracy at all quality-control levels. Pediatric RIs provided a quantitative framework for interpreting the metabolic abnormalities. In IEM patients, disease-specific metabolites were consistently outside the established ranges, and z-score-based logistic regression models successfully distinguished major IEM categories, including organic acidemias and long-chain fatty acid oxidation disorders. Conclusions: This fully automated, serum-based LC–MS/MS platform provides a clinically practical and quantitative framework for integrated metabolic profiling using pediatric RIs, supporting diagnosis and monitoring of IEMs in pediatric settings.


  • Open Access

    Multi-Omics Mapping of Human Kidney Reveals Complement-Mediated Cellular Dynamics During Progression of Focal Segmental Glomerulosclerosis

    by Sahomi Hayashi, Miyoshi Takeuchi, Toshiaki Nakano, Daiki Setoyama, Sasha A. Singh, Abhijeet R. Sonawane, Takaki Iwamoto, Hiroshi Kishimoto, Akihiro Tsuchimoto, Shunsuke Yamada, et al.

    Focal segmental glomerulosclerosis (FSGS) is a major cause of glucocorticoid-resistant nephrosis, yet its pathogenesis remains unclear. To define the molecular and cellular landscape of FSGS, we employed multi-omics approaches on independent human kidney biopsy cohorts. Proteomics revealed enhanced immune and complement activation. Spatial transcriptomics using a target gene panel constructed from the proteomics highlighted alternative pathway activation driven by complement factor D as a prominent feature. Complement activation emerged in glomeruli alongside altered signaling in podocytes and parietal epithelial cells (PECs): Podocytes displayed reduced PECAM1 and elevated macrophage migration inhibitory factor (MIF) signaling, and PECs display complement and collagen signaling as early events, and progressively acquired cellular activation, prompting glomerular fibrosis. These pathogenic signals propagated into adjacent interstitial regions, paralleling immune cell infiltration and fibrosis. These results uncover dynamics of dysregulated intercellular interactions originated from podocyte and PECs underlying the pathogenesis of FSGS, which provides insights into potential stage-specific interventions.

  • Objective quantification of pre-CAR-T EEG abnormalities for ICANS prognosis: insights from GTE scoring

    by Hidetaka Nakagaki, Takuji Yamauchi, Takahiko Mukaino, Ayumi Sakata, Eriko Watanabe, Mitsuru Watanabe, Daisuke Ishihara, Hiroshi Imanaga, Kensuke Sasaki, Teppei Sakoda, et al.


  • Open Access

    Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy

    by Tomoko Nomiyama, Daiki Setoyama, Ikumi Yamanaka, Masatoshi Shimo, Kohta Miyawaki, Takuji Yamauchi, Fumiaki Jinnouchi, Teppei Sakoda, Kensuke Sasaki, Takahiro Shima, et al.


  • Open Access

    Pre-CAR-T GTE Scoring of Electroencephalogram Abnormalities as a Predictive Biomarker for ICANS

    by Koji Kato, Hidetaka Nakagaki, Takuji Yamauchi, Takahiro Mukaino, Ayumi Sakata, Eriko Watanabe, Mitsuru Watanabe, Daisuke Ishihara, Hiroshi Imanaga, Kensuke Sasaki, et al.

    CD19-targeted chimeric antigen receptor (CAR)-T cell therapy is an effective treatment for relapsed or refractory B-cell lymphoma but is associated with adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The pathogenesis of ICANS remains unclear, and predictive biomarkers are needed for risk stratification. This study evaluates the Grand Total EEG (GTE) score, a comprehensive scoring system for electroencephalogram (EEG) abnormalities, as a predictive biomarker for ICANS. We retrospectively analyzed 55 patients who underwent CAR-T cell therapy. ICANS occurred in 29% of patients, with CRS (grade ≥ 2) and axicabtagene ciloleucel identified as significant risk factors. Higher GTE scores correlated with ICANS severity after ICANS onset. Furthermore, the GTE score before CAR-T therapy was already significantly higher in the ICANS group (mean: 4.94 ± 3.11) than in the non-ICANS group (mean: 2.44 ± 1.71) with an odds ratio of 1.78. Patients with a history of high-dose methotrexate treatment showed elevated GTE scores, suggesting an association between CNS-targeted therapies and baseline brain dysfunction without symptoms. The findings of this study illustrate the efficacy of the GTE score as a novel biomarker for ICANS prediction. The score enables early risk stratification and directs interventions in CAR-T therapy.

  • Open Access

    A nucleic acid prodrug that activates mitochondrial respiration, promotes stress resilience, and prolongs lifespan

    by Takahisa Anada, Michiharu Kawahara, Taisei Shimada, Ryotaro Kuroda, Hidenori Okamura, Daiki Setoyama, Fumi Nagatsugi, Yuya Kunisaki, Eriko Kage-Nakadai, Shingo Kobayashi, et al.

    Mitochondrial dysfunction caused by aging leads to decreased energy metabolism, resulting in functional decline and increased frailty in multiple tissues. Strategies for protecting and activating mitochondria under stressful conditions are required to suppress aging and age-related diseases. However, it is challenging to develop drugs capable of boosting mitochondrial respiration and compensating for the reduced intracellular adenosine triphosphate (ATP) levels. In this study, we developed a prodrug that stimulates the metabolism of intracellular adenine nucleotides (AXP: adenosine monophosphate (AMP), adenosine diphosphate (ADP), and ATP). It enhances AMP-activated protein kinase activity, fatty acid oxidation, oxidative stress resistance, and mitochondrial respiration, thereby increasing the intracellular ATP levels. Furthermore, this prodrug markedly extended the lifespan of Caenorhabditis elegans . AXP-driven stimulation of cellular energy metabolism proposed herein represents a novel geroprotective strategy and paves the way for the development of bioenergetic-molecule therapeutics.

  • Open Access

    Collagen Lattice Model, Populated with Heterogeneous Cancer-Associated Fibroblasts, Facilitates Advanced Reconstruction of Pancreatic Cancer Microenvironment

    by Xiaoyu Song, Yuma Nihashi, Yukiko Imai, Nobuhito Mori, Noritaka Kagaya, Hikaru Suenaga, Kazuo Shin-Ya, Masamichi Yamamoto, Daiki Setoyama, Yuya Kunisaki, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is a solid-tumor malignancy. To enhance the treatment landscape of PDAC, a 3D model optimized for rigorous drug screening is essential. Within the PDAC tumor microenvironment, a dense stroma comprising a large extracellular matrix and cancer-associated fibroblasts (CAFs) is well-known for its vital role in modulating tumor growth, cellular heterogeneity, bidirectional paracrine signaling, and chemoresistance. In this study, we employed a fibroblast-populated collagen lattice (FPCL) modeling approach that has the ability to replicate fibroblast contractility in the collagenous matrix to build dense stroma. This FPCL model allows CAF differentiation by facilitating multifaceted cell–cell interactions between cancer cells and CAFs, with the differentiation further influenced by mechanical forces and hypoxia carried within the 3D structure. Our FPCL models displayed hallmark features, including ductal gland structures and differentiated CAFs with spindle shapes. Through morphological explorations alongside in-depth transcriptomic and metabolomic profiling, we identified substantial molecular shifts from the nascent to mature model stages and potential metabolic biomarkers, such as proline. The initial pharmacological assays highlighted the effectiveness of our FPCL model in screening for improved therapeutic strategies. In conclusion, our PDAC modeling platform mirrors complex tumor microenvironmental dynamics and offers an unparalleled perspective for therapeutic exploration.


  • Prognostic impact of HLA supertype mismatch in single-unit cord blood transplantation

    by Takeshi Sugio, Naoyuki Uchida, Kohta Miyawaki, Yuju Ohno, Tetsuya Eto, Yasuo Mori, Goichi Yoshimoto, Yoshikane Kikushige, Yuya Kunisaki, Shinichi Mizuno, et al.

    The “human leukocyte antigen (HLA) supertype” is a functional classification of HLA alleles, which was defined by structural features and peptide specificities, and has been reportedly associated with the clinical outcomes of viral infections and autoimmune diseases. Although the disparity in each HLA locus was reported to have no clinical significance in single-unit cord blood transplantation (sCBT), the clinical significance of the HLA supertype in sCBT remains unknown. Therefore, we retrospectively analyzed clinical data of 1603 patients who received sCBT in eight institutes in Japan between 2000 and 2017. Each HLA allele was categorized into 19 supertypes, and the prognostic effect of disparities was then assessed. An HLA-B supertype mismatch was identified as a poor prognostic factor (PFS: hazard ratio [HR] = 1.23, p = 0.00044) and was associated with a higher cumulative incidence (CI) of relapse (HR = 1.24, p = 0.013). However, an HLA-B supertype mismatch was not associated with the CI of acute and chronic graft-versus-host-disease. The multivariate analysis for relapse and PFS showed the significance of an HLA-B supertype mismatch independent of allelic mismatches, and other previously reported prognostic factors. HLA-B supertype-matched grafts should be selected in sCBT.